Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis (nash) in five european countries in 2018: A cost-of-illness analysis.

Schattenberg, Jörn M, Lazarus, Jeffrey V, Newsome, Philip N, Serfaty, Lawrence, Aghemo, Alessio, Augustin, Salvador, Tsochatzis, Emmanuel, de Ledinghen, Victor, Bugianesi, Elisabetta, Romero-Gomez, Manuel, Bantel, Heike, Ryder, Stephen D, Boursier, Jerome, Leroy, Vincent, Crespo, Javier, Castera, Laurent, Floros, Lefteris, Atella, Vincenzo, Mestre-Ferrandiz, Jorge, Elliott, Rachel, Kautz, Achim, Morgan, Alice, Hartmanis, Sally, Vasudevan, Sharad, Pezzullo, Lynne, Trylesinski, Aldo, Cure, Sandrine, Higgins, Victoria and Ratziu, Vlad (2021) Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis (nash) in five european countries in 2018: A cost-of-illness analysis. Liver international : official journal of the International Association for the Study of the Liver. ISSN 1478-3231. This article is available to all UHB staff and students via ASK Discovery tool http://tinyurl.com/z795c8c by using their UHB Athens login IDs

Full text not available from this repository.
Official URL: http://onlinelibrary.wiley.com/journal/10.1111/(IS...

Abstract

BACKGROUND AND AIMS

Non-alcoholic steatohepatitis (NASH) is a chronic disease that can progress to end-stage liver disease (ESLD). A large proportion of early-stage NASH patients remain undiagnosed compared to those with advanced fibrosis, who are more likely to receive disease management interventions. This study estimated the disease burden and economic impact of diagnosed NASH in the adult population of France, Germany, Italy, Spain and the United Kingdom (UK) in 2018.

METHODS

The socioeconomic burden of diagnosed NASH was estimated using cost-of-illness methodology applying a prevalence approach to estimate the number of adults with NASH and the attributable economic and wellbeing costs. Given undiagnosed patients do not incur costs in the study, the probability of diagnosis is central to cost estimation. The analysis was based on literature review, databases and consultation with clinical experts, economists and patient groups.

RESULTS

The proportion of adult NASH patients with a diagnosis ranged from 11.9% to 12.7% across countries, which increased to 38.8% to 39.1% for advanced fibrosis (F3 to F4 compensated cirrhosis). Total economic costs were €8,548-19,546M. Of these, health system costs were €619-1,292M. Total wellbeing costs were €41,536-90,379M. The majority of the undiagnosed population (87.3% to 88.2% of total prevalence) was found to have early stage NASH which, left untreated, may progress to more resource consuming ESLD over time.

CONCLUSIONS

This study found the majority of economic and wellbeing costs of NASH are experienced in late disease stages. Earlier diagnosis and care of NASH patients could reduce future healthcare costs.

Item Type: Article
Additional Information: This article is available to all UHB staff and students via ASK Discovery tool http://tinyurl.com/z795c8c by using their UHB Athens login IDs
Subjects: QA Mathematics. Computing
W Public health. Health statistics. Occupational health. Health education
WI Digestive system. Gastroenterology
Divisions: Planned IP Care > Gastroentrology
Related URLs:
Depositing User: Jamie Edgar
Date Deposited: 24 Feb 2021 15:38
Last Modified: 24 Feb 2021 15:38
URI: http://www.repository.uhblibrary.co.uk/id/eprint/4006

Actions (login required)

View Item View Item